Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They announce any news in this market and blows past $1
This morning ASK over .12.......news coming!
Looks like this will be slowly dripping down for a long time..Could be a sleeping monster though...
Looks like they literally drops everything.
Any news on NXEN-04? Looks like they put out news in Feb 2019 for Pre-IND meeting w FDA? Then nothing after that?
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Nexien BioPharma, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Nexien BioPharma, Inc. (the Company) as of June 30, 2020 and 2019, and the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended June 30, 2020, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two-year period ended June 30, 2020, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, since inception, the Company has not established any source of revenue to cover operating costs and has suffered net losses that have resulted in an accumulated deficit, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ M&K CPAS, PLLC
We have served as the Company’s auditor since 2017.
Houston, Texas
September 28, 2020
F-1
https://seekingalpha.com/filings/pdf/14410162.pdf
IMO, This is a standard Auditor's statement. Having the financials audited is very important.
Based on what? Lol. It has future potential but its not there yet
Cryptic. What's happening on the 16th?
A little more patience, this will start moving
Hmm a few more form 4s dropped today. Insiders acquiring millions of shares
Greenberg filed a form 4, probably so he can dump his shares on the market at current pps
I wiped my ass with a few shares this morning and flushed them
what good is a patent if you arent going to use it? Green berg is just gonna sit and wait for a buyout while this goes to 01 or 0001 I should say
I honestly dont think this is going much lower than where it is, Volume dried up cuz the company is not that great a communicating with shareholders, once News hit this will break .50 in a day, 10 million float can move real fast , I rather wait for solid news than having fluff every week GLTA $NXEN
To be honest I am surprised the way it ran due to the patent. I think this is going back down or lower until some solid real news about Clinical Trial. No bashing. Just saying.
maybe next year it will pop and I can get my money back, good luck
Just like me after I bought this stock, broke
Patents arent worth the paper they are printed on unless you actually use it.....
This is looking good. Up we shall go.
YUP, IM SURE $NXEN WILL MOVE UP SOON
You probably bought way too high, you'll get your money back patience will pay off here... 1o million float with no debts in OTC, this is golden, just hasn't got attention yet some ppl flipped and left, thats ok, once news hit this will go to dollars relax $NXEN
Oh yea and the phone is disconnected
Biggest pos I’ve gotten bagged on in a while
I expect .04-05 within another week
Accumulation is the key word here.
The second key word here is patience
Those who exercise both will be sitting pretty in a few months.
Don't forget, human clinical trials begin in the 4th quarter of 2020.
Only up from here $NXEN
Let me guess...
It a share selling scawm.LOL
What a wealth of knowledge you are! I totally enjoy reading your deep informative posts.
NOT!!!!
$NXEN looking great today
US patent was approved under same CEO.
Need some patience
Followers
|
51
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3866
|
Created
|
03/13/07
|
Type
|
Free
|
Moderators |
Nexien BioPharma’s drug development strategy consists of:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |